Sickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review buff.ly/zcGQyBq #hemesky #clinicaltrialsandobservations #redcellsironanderythropoiesis #SCD
March 29, 2025 at 5:03 PM
Sickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review buff.ly/zcGQyBq #hemesky #clinicaltrialsandobservations #redcellsironanderythropoiesis #SCD
Oligocentric CD is an intermediate phenotype distinctly characterized from unicentric and iMCD. buff.ly/zOHYxKF #hemesky #clinicaltrialsandobservations
May 5, 2025 at 2:06 PM
Oligocentric CD is an intermediate phenotype distinctly characterized from unicentric and iMCD. buff.ly/zOHYxKF #hemesky #clinicaltrialsandobservations
Model-based dosing is easy to implement and can improve outcome of pediatric HCT. buff.ly/aLfhdMy #hemesky #clinicaltrialsandobservations #transplantion
May 17, 2025 at 4:02 PM
Model-based dosing is easy to implement and can improve outcome of pediatric HCT. buff.ly/aLfhdMy #hemesky #clinicaltrialsandobservations #transplantion
Patients with FLT3-ITD AML in remission are commonly offered alloHCT as a final consolidative therapy. buff.ly/HDFlnGd #hemesky #clinicaltrialsandobservations
May 11, 2025 at 1:02 PM
Patients with FLT3-ITD AML in remission are commonly offered alloHCT as a final consolidative therapy. buff.ly/HDFlnGd #hemesky #clinicaltrialsandobservations
Daily subcutaneous anakinra is insufficient to prevent grade ≥2 CRS and NT in patients receiving axicabtagene ciloleucel. buff.ly/1afpMwo #hemesky #clinicaltrialsandobservations #lymphoidneoplasia
May 14, 2025 at 3:02 PM
Daily subcutaneous anakinra is insufficient to prevent grade ≥2 CRS and NT in patients receiving axicabtagene ciloleucel. buff.ly/1afpMwo #hemesky #clinicaltrialsandobservations #lymphoidneoplasia
Apart from COVID-19–related adverse events, the triple combination was well tolerated. buff.ly/ARqMYrh #clinicaltrialsandobservations #lymphoidneoplasia #hemesky
March 26, 2025 at 4:06 PM
Apart from COVID-19–related adverse events, the triple combination was well tolerated. buff.ly/ARqMYrh #clinicaltrialsandobservations #lymphoidneoplasia #hemesky
Salvage autologous transplant vs lenalidomide/dexamethasone offers no significant survival benefit in RRMM. buff.ly/vq0OGYy #hemesky #clinicaltrialsandobservations
April 22, 2025 at 2:03 PM
Salvage autologous transplant vs lenalidomide/dexamethasone offers no significant survival benefit in RRMM. buff.ly/vq0OGYy #hemesky #clinicaltrialsandobservations
Small-molecule inhibitors offer survival advantage relative to chemotherapy in AITL, warranting continued investigation in clinical trials. https://buff.ly/3QhYQzm #lymphoidneoplasia #clinicaltrialsandobservations
February 12, 2025 at 10:01 PM
Small-molecule inhibitors offer survival advantage relative to chemotherapy in AITL, warranting continued investigation in clinical trials. https://buff.ly/3QhYQzm #lymphoidneoplasia #clinicaltrialsandobservations
Dasatinib, asciminib, and prednisone can be safely combined for the dual targeting of BCR::ABL1 in Ph+ acute leukemia. https://buff.ly/40QKpao #clinicaltrialsandobservations #lymphoidneoplasia
February 7, 2025 at 9:00 PM
Dasatinib, asciminib, and prednisone can be safely combined for the dual targeting of BCR::ABL1 in Ph+ acute leukemia. https://buff.ly/40QKpao #clinicaltrialsandobservations #lymphoidneoplasia
Itacitinib resulted in low rates of CRS, acute and chronic GVHD, and encouraging GVHD-free relapse-free survival and OS after haplo-HCT. buff.ly/sC0gLb1 #clinicaltrialsandobservations #myeloidneoplasia #transplantation
April 1, 2025 at 5:01 PM
Itacitinib resulted in low rates of CRS, acute and chronic GVHD, and encouraging GVHD-free relapse-free survival and OS after haplo-HCT. buff.ly/sC0gLb1 #clinicaltrialsandobservations #myeloidneoplasia #transplantation
Ibrutinib and nivolumab showed a response rate of 78% and the best complete response rate was 50% for relapsed/refractory CNS lymphomas. buff.ly/sRhBx7C #hemesky #clinicaltrialsandobservations
April 21, 2025 at 2:03 PM
Ibrutinib and nivolumab showed a response rate of 78% and the best complete response rate was 50% for relapsed/refractory CNS lymphomas. buff.ly/sRhBx7C #hemesky #clinicaltrialsandobservations
After blinatumomab, MRD negativity rate was 93%; 3-year survival rate was 93% and 65% in chemotherapy and HSCT groups, respectively. buff.ly/T5nNHKI #hemesky #clinicaltrialsandobservations #lymphoidneoplasia
May 26, 2025 at 3:03 PM
After blinatumomab, MRD negativity rate was 93%; 3-year survival rate was 93% and 65% in chemotherapy and HSCT groups, respectively. buff.ly/T5nNHKI #hemesky #clinicaltrialsandobservations #lymphoidneoplasia
Florida’s high rates of leukemia are influenced by population aging and indicate future needs for leukemia health care in the United States. buff.ly/x5ma75j #hemesky #clinicaltrialsandobservations
May 22, 2025 at 7:02 PM
Florida’s high rates of leukemia are influenced by population aging and indicate future needs for leukemia health care in the United States. buff.ly/x5ma75j #hemesky #clinicaltrialsandobservations
Dara-CyBorD frontline therapy improves survival and reduces early death in AL amyloidosis. buff.ly/xz7OyPm #hemesky #clinicaltrialsandobservations
May 22, 2025 at 5:02 PM
Dara-CyBorD frontline therapy improves survival and reduces early death in AL amyloidosis. buff.ly/xz7OyPm #hemesky #clinicaltrialsandobservations
Dara-CyBorD frontline therapy improves survival and reduces early death in AL amyloidosis. buff.ly/xz7OyPm #hemesky #clinicaltrialsandobservations
May 22, 2025 at 3:04 PM
Dara-CyBorD frontline therapy improves survival and reduces early death in AL amyloidosis. buff.ly/xz7OyPm #hemesky #clinicaltrialsandobservations
Foundation for future studies on gut microbiota-sparring strategies in ALL treatment to improve immune recovery. buff.ly/TB5Cxbs #hemesky #clinicaltrialsandobservations
April 15, 2025 at 5:03 PM
Foundation for future studies on gut microbiota-sparring strategies in ALL treatment to improve immune recovery. buff.ly/TB5Cxbs #hemesky #clinicaltrialsandobservations
Lower C3 levels were associated with a higher likelihood of developing HLH. buff.ly/YwWo5J1 #hemesky #clinicaltrialsandobservations
May 9, 2025 at 2:05 PM
Lower C3 levels were associated with a higher likelihood of developing HLH. buff.ly/YwWo5J1 #hemesky #clinicaltrialsandobservations
Surgical resection and BRAF or MEK inhibitors demonstrated the highest response rates, yet the prognosis of MH remains poor. buff.ly/ZeeTuH5 #hemesky #clinicaltrialsandobservations
June 1, 2025 at 1:02 PM
Surgical resection and BRAF or MEK inhibitors demonstrated the highest response rates, yet the prognosis of MH remains poor. buff.ly/ZeeTuH5 #hemesky #clinicaltrialsandobservations
Foundation for future studies on gut microbiota-sparring strategies in ALL treatment to improve immune recovery. buff.ly/TuKxmDS #hemesky #clinicaltrialsandobservations
April 14, 2025 at 5:02 PM
Foundation for future studies on gut microbiota-sparring strategies in ALL treatment to improve immune recovery. buff.ly/TuKxmDS #hemesky #clinicaltrialsandobservations
Glucarpidase receipt was also associated with a lower adjusted odds of grade ≥2 transaminitis and grade ≥2 neutropenia. buff.ly/Jn0v4L2 #hemesky #clinicaltrialsandobservations
April 30, 2025 at 6:02 PM
Glucarpidase receipt was also associated with a lower adjusted odds of grade ≥2 transaminitis and grade ≥2 neutropenia. buff.ly/Jn0v4L2 #hemesky #clinicaltrialsandobservations
Nivo maintenance after AML chemotherapy did not improve the PFS and OS in this randomized phase 2 study. buff.ly/f90igQZ #hemesky #clinicaltrialsandobservations #myeloidneoplasia
May 14, 2025 at 6:02 PM
Nivo maintenance after AML chemotherapy did not improve the PFS and OS in this randomized phase 2 study. buff.ly/f90igQZ #hemesky #clinicaltrialsandobservations #myeloidneoplasia
Longer ibrutinib lead-in phase decreases TLS risk, and a minimum of 24-month IV combination enhances uMRD CR/CRi rates. buff.ly/gzGEDtF #hemesky #clinicaltrialsandobservations
May 30, 2025 at 6:01 PM
Longer ibrutinib lead-in phase decreases TLS risk, and a minimum of 24-month IV combination enhances uMRD CR/CRi rates. buff.ly/gzGEDtF #hemesky #clinicaltrialsandobservations
Higher ORR and CR rate in less heavily pretreated patients suggest that this regimen, as an earlier treatment, may improve outcomes. buff.ly/bi4dpzR #hemesky #clinicaltrialsandobservations
April 14, 2025 at 3:05 PM
Higher ORR and CR rate in less heavily pretreated patients suggest that this regimen, as an earlier treatment, may improve outcomes. buff.ly/bi4dpzR #hemesky #clinicaltrialsandobservations
Venetoclax plus modified intensive chemotherapy (CAVEAT) is well tolerated and effective (75% remission) in fit, older patients with AML. buff.ly/yYKRjn5 #hemesky #clinicaltrialsandobservations #myeloidneoplasia
May 10, 2025 at 2:03 PM
Venetoclax plus modified intensive chemotherapy (CAVEAT) is well tolerated and effective (75% remission) in fit, older patients with AML. buff.ly/yYKRjn5 #hemesky #clinicaltrialsandobservations #myeloidneoplasia
Most patients with pre-HCT MRD clear MRD by day +70 to +100 but outcomes are substantially worse relative to MRDneg/MRDneg patients. https://buff.ly/3CPzeXw #transplantation #myeloidneoplasia #clinicaltrialsandobservations
February 13, 2025 at 1:08 PM
Most patients with pre-HCT MRD clear MRD by day +70 to +100 but outcomes are substantially worse relative to MRDneg/MRDneg patients. https://buff.ly/3CPzeXw #transplantation #myeloidneoplasia #clinicaltrialsandobservations